A Facebook Reel points to a real research frontier around low-dose LSD, psychedelics, neuroplasticity and dementia. It does not prove that LSD treats Alzheimer’s disease.
Norman Ohler says he found Eleusis material on LSD and dementia-related receptors, discussed it with his father, and later saw his mother with Alzheimer’s become more lively after a microdose.
| Source | What it supports | What it does not prove |
|---|---|---|
| PubMed 31853557 | Repeated 5/10/20 microgram LSD was reported well tolerated in 48 healthy older volunteers over 21 days. | Not an Alzheimer’s patient efficacy trial. |
| PubMed 32973482 | Review argues psychedelics are interesting candidates because of neuroplasticity/neuroinflammation hypotheses. | Review-level possibility, not clinical proof. |
| PubMed 38307424 | Reviews possible pathways in Alzheimer’s-related dementia: 5-HT, BDNF, mTOR, autophagy. | Mechanistic exploration, not a treatment recommendation. |
| PubMed 41707907 | Describes mitochondrial-centered hallucinogenic therapy as a hypothesis-generating model. | States clinical efficacy evidence remains limited and largely preclinical. |
| ClinicalTrials.gov NCT04123314 | Shows psychedelic research in MCI/early Alzheimer’s depression symptoms. | Not completed proof that LSD reverses Alzheimer’s. |
Prepared for Managing Expectations. No passwords, tokens, local credential paths, or private medical information are included.